(+)-Epibatidine

(+)-Epibatidine

SCHEMBL316977

Clc1ccc([C@@H]2C[C@H]3CC[C@@H]2N3)cn1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 7/20 1.00
CHRNA4 P43681 7/20 1.00
CHRNA7 P36544 4/20 1.00
CHRNB4 P30926 4/20 1.00
CHRNA3 P32297 4/20 1.00
ALDH1A1 P00352 2/20 1.00
CHRNA2 Q15822 2/20 1.00
MEN1 O00255 1/20 1.00
KMT2A Q03164 1/20 1.00
CHRNA1 P02708 1/20 1.00
CHRNG P07510 1/20 1.00
CHRNB1 P11230 1/20 1.00
HPGD P15428 1/20 1.00
CHRND Q07001 1/20 1.00
TDP1 Q9NUW8 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Epibatidine SCHEMBL316978 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
(-)-Epibatidine SCHEMBL2500147 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
Epibatidine SCHEMBL9070584 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
Epibatidine SCHEMBL29390446 1.00 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
(+)-Epibatidine SCHEMBL5267259 0.98 CHRNA7 (1.00) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
(+)-Epibatidine SCHEMBL6264689 0.98 CHRNB2 (0.97) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
Epibatidine SCHEMBL5969577 0.98 CHRNA7 (1.00) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
Homoepibatidine SCHEMBL29711361 0.91 CHRNB2 (1.00) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL7663147 0.84 CHRNB2 (0.72) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3
SCHEMBL13596272 0.84 CHRNB2 (0.72) CHRNB2CHRNA4CHRNA7CHRNB4CHRNA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 2447 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4255391-B1 LUMINOL FOR USE IN THE TREATMENT OF SEQUELAE OF A SARS-COV-2 INFECTION METRIOPHARM AG (CH) 2026-05-06 EP claimed
WO-2025037323-A1 PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF DRY EYE DISEASE AND ASSOCIATED DISORDERS KOTHAPUVARI PAVAN KUMAR (IN) 2025-02-20 WO claimed
WO-2025027196-A1 A METHOD OF PRODUCING NANOPARTICLES OF A DEFINED SIZE IQ MEDICAL GMBH (DE) 2025-02-06 WO claimed
WO-2025027194-A1 A METHOD OF PREPARING AN AQUEOUS DISPERSION OF NANOPARTICLES IQ MEDICAL GMBH (DE) 2025-02-06 WO claimed
EP-4501320-A1 A METHOD OF PREPARING AN AQUEOUS DISPERSION OF NANOPARTICLES IQ medical GmbH (DE) 2025-02-05 EP claimed
US-20250032503-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE HOTH THERAPEUTICS, INC. 2025-01-30 US claimed
US-20240329053-A1 A CELL-BASED METHOD FOR DETECTING POTENTIALLY PATHOGENIC AUTOANTIBODIES TO NEURONAL NICOTINIC ACETYLCHOLINE RECEPTORS TZARTOS NEURODIAGNOSTICS (GR) 2024-10-03 US claimed
US-20240173318-A1 DRY EYE TREATMENTS OYSTER POINT PHARMA INC (US) 2024-05-30 US claimed
EP-4297868-A1 USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE Hoth Therapeutics, Inc. (US) 2024-01-03 EP claimed
WO-2023212244-A1 METHODS OF TREATING 5HT2A RECEPTOR-MEDIATED CONDITIONS TESSELLATE THERAPEUTICS, INC. (US) 2023-11-02 WO claimed
WO-2001058951-A2 WATER-SOLUBLE LIGAND-BINDING PROTEINS OF LIGAND-GATED ION CHANNELS, CRYSTALS THEREOF AND THEIR USE FOR SCREENING LIGANDS OF LIGAND-GATED ION CHANNELS STICHTING VOOR DE TECHNISCHE WETENSCHAPPEN (NL) 2001-08-16 WO claimed
US-6252132-B1 Mutant mouse containing a knockout mutation in DNA encoding an endogenous alpha 4 subunit of nicotinic acetylcholine receptor INSTITUT PASTEUR (FR) 2001-06-26 US claimed
WO-2000045846-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING NICOTINE OR A LIGAND OF NICOTINE RECEPTORS AND A MONAMINE OXYDASE INHIBITOR AND THEIR USE FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS SANOFI-SYNTHELABO (FR) 2000-08-10 WO claimed
WO-2000026392-A2 MUTANT MOUSE CONTAINING A KNOCKOUT MUTATION IN DNA ENCODING AN ENDOGENOUS α4 SUBUNIT OF NICOTINIC ACETYLCHOLINE RECEPTOR INSTITUT PASTEUR (FR) 2000-05-11 WO claimed
EP-0657456-B1 Process for preparing epibatidine EGYT GYOGYSZERVEGYESZETI GYAR (HU) 1997-06-04 EP claimed
US-5565573-A Synthesis of epibatidine and analogs thereof IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. (US) 1996-10-15 US claimed
EP-0736534-A1 Process for preparing epibatidine EGIS GYOGYSZERGYAR RT. (HU) 1996-10-09 EP claimed
US-5545741-A Process for the preparation of epibatidine EGIS GYOGYSZERGYAR RT. (HU) 1996-08-13 US claimed
US-5510490-A Process for the preparation of epibatidine COUNCIL OF SCIENTIFIC & INDUSTRIAL RESEARCH (IN) 1996-04-23 US claimed
EP-0657456-A1 Process for preparing epibatidine EGIS GYOGYSZERGYAR RT. (HU) 1995-06-14 EP claimed